HDAC inhibitors conquer polycomb proteins
نویسندگان
چکیده
منابع مشابه
HDAC Inhibitors and Heat Shock Proteins (Hsps)
Epigenetic alterations, including DNA acetylation, hypermethylation and hypomethylation, and the associated transcriptional changes of the affected genes are central to the evolution and progression of various human cancers, including pancreatic cancer. Cancer-associated epigenetic alterations are attractive therapeutic targets because such epigenetic alterations, unlike genetic changes, are po...
متن کاملHDAC inhibitors repress the polycomb protein BMI1
2704 Cell Cycle Volume 9 Issue 14 Several studies recently unveiled the involvement of the Polycomb group (PcG) proteins, most notably Bmi-1 and EZH2, in the occurrence of various human cancers and maintenance of the invasive phenotype. The PcG proteins are typically involved in the transcriptional silencing of their target genes through epigenetic mechanisms resulting in chromatin compaction. ...
متن کاملhdac inhibitors in neurodegenerative disorders
neurodegenerative disorders such as huntingtons disease, alzheimers disease, parkinsons disease, amyotrophic lateral sclerosis, spinal muscular atrophy, friedreichs ataxia, and others are multi-factorial illnesses in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. thus, presently there are no effective cures for these disease...
متن کاملRational combinations using HDAC inhibitors.
In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs. In numerous in vitro and preclinical settings, the...
متن کاملHDAC inhibitors and cardiac safety.
To the Editors: Shah et al. (1) reported on the cardiotoxicity of the histone deacetylase inhibitor Romidepsin (depsipeptide, FK228) administered weekly 3 q28, in 15 patients with metastatic neuroendocrine tumors. The study was terminated early due to a high number of ‘‘serious cardiac adverse events’’ comprising of one sudden death, asymptomatic grade 2 ventricular tachycardia in two patients,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell Cycle
سال: 2010
ISSN: 1538-4101,1551-4005
DOI: 10.4161/cc.9.14.12323